Introduction
Early gastric cancer (EGC) is defi ned as gastric cancer confi ned to the mucosa or submucosa, regardless of the presence or absence of lymph node (LN) metastasis [1] . In the Eastern hemisphere, up to 70% of all gastric cancers are diagnosed as EGCs (due to mass population screening), whereas in the Western hemisphere, the rate of gastric cancers identifi ed as EGCs accounts for only about 15% [2] . EGC shows a favorable prognosis compared to advanced gastric cancer, with 5-year cancer-specifi c survival rates exceeding 95% [3] . Accurate prediction of LN status is of crucial importance for appropriate curative treatment planning in EGC; LNnegative patients can be curatively treated with minimally invasive endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) [3] , whereas LN-positive patients should undergo (sub) total gastrectomy with limited or extended LN dissection [4] . Gastrectomy with LN dissection is associated with high morbidity and mortality [4] , and postoperative quality of life may be impaired because of weight loss, loss of appetite, and other metabolic and nutritional changes. Therefore, this aggressive surgical approach should be reserved only for EGC patients at high risk of LN metastasis. In an attempt to obtain predictive parameters, multiple studies have identifi ed pathologic characteristics of the primary tumor that are associated with an increased likelihood of LN metastasis. Because established eligibility criteria for endoscopic resection of EGC [5] are debated [3, 6] , we undertook a systematic review and meta-analysis to give more insight into those patient and/or tumor characteristics that emerge as associated with LN metastasis in EGC.
Methods

Data sources
A computer-aided search of the PubMed/MEDLINE database was conducted to fi nd English-language studies which reported patient and/or tumor characteristics in relation to LN metastasis in patients with EGC. The following search term was used: "node metastasis" or "node metastases" or "nodal metastasis" or "nodal metastases" or "node involvement" or "nodal involvement" or "metastatic nodes" or "metastatic lymph nodes" or "lymphatic metastasis" or "lymphatic metastases" or "lymphatic involvement" or "lymph node metastatic disease" and ("gastric cancer" or "stomach cancer" or "gastric carcinoma" or "stomach carcinoma"). No beginning date limit was used. The search was updated until 30 October, 2007 . To expand the search, bibliographies of articles which fi nally remained after the selection process were screened for potentially suitable references.
Eligibility criteria
Original studies which investigated the relationship between patient and/or tumor characteristics and the presence or absence of LN metastasis in patients with histopathologically proven EGC were eligible for inclusion. EGC was defi ned as a tumor histopathologically confi ned to the mucosa or submucosa, regardless of disease duration, tumor size, presence of symptoms, presence of metastases, or curability [1] . Because risk of LN metastasis is substantially higher in gastric cancer invading the submucosa (submucosal cancer) than in gastric cancer limited to the mucosa (mucosal cancer), only studies which provided separate data for mucosal and/or submucosal cancer were included. Studies performed in animals, ex vivo studies, review articles, meta-analyses, abstracts, editorials or letters, case reports, studies investigating 15 or fewer patients, tutorials, and guidelines for management were excluded. Studies which only investigated the association between patient and/or tumor characteristics and immunohistochemically detected LN micrometastases were also excluded, because these LNs are regarded as pathologically negative for metastatic disease [7] . Only studies dealing with carcinoma were included, because this is overwhelmingly the most important and most common malignant tumor that occurs in the stomach (range, 90% to 95%) [1] . Studies which investigated only a specifi c type of gastric cancer (i.e., differentiated or undifferentiated gastric cancer, gastric cancer confi ned to a specifi c part of the stomach, or depressed gastric cancer) were excluded. Only studies which provided suffi cient data to construct a 2 × 2 contingency table to calculate the association of one or more patient and/or tumor characteristics with LN metastasis were included. Among studies that (possibly) included overlapping patient populations, the article with the highest number of patients was selected for further analysis. However, (possibly) overlapping studies comprising a lower number of patients were also included if they investigated other patient and/or tumor characteristics than the ones in the study with the highest number of patients. In such cases, data analysis was performed only for the patient and/or tumor characteristics or type of EGC (i.e., either mucosal or submucosal cancer), which had not been investigated in the study with the highest number of patients.
Titles and abstracts of the retrieved articles were screened by two researchers (R. M. K. and T. C. K.), using the inclusion and exclusion criteria as mentioned above. Articles were rejected if they were clearly ineligible. Full-text versions of all articles that were found to be potentially eligible for inclusion were then evaluated to make a fi nal decision regarding inclusion or exclusion. Discrepancies between the two researchers were solved by consensus.
Data analysis
For each included study, information was collected concerning the year of publication, country of origin, patient acquisition (consecutive vs nonconsecutive), number of investigated patients, percentage of patients with LN metastasis, extent of lymphadenectomy, variables in relation to LN metastasis analyzed in this review, blind assessment of variables to LN status, and blind assessment of LN status to the investigated variables.
Because of the use of various defi nitions, the variables "macroscopic tumor type", "histological type", "depth of mucosal or submucosal invasion", "vascular tumor invasion", and "lymphatic tumor invasion" were classifi ed into dichotomized groups. Macroscopic tumor type was divided into depressed and nondepressed types. Among studies which applied the Japanese classifi cation of gastric carcinoma [8] (2) defi ned according to the Lauren classifi cation (which classifi es gastric cancer into either intestinal or diffuse type) [9] . Well-and moderately differentiated tubular or papillary adenocarcinomas were classifi ed as being differentiated. Poorly differentiated adenocarcinomas and signet-ring cell carcinomas were classifi ed as being undifferentiated. Mucinous adenocarcinomas were classifi ed as either differentiated or undifferentiated, depending upon the other predominant elements (tubular, papillary, poorly differentiated, or signet-ring cell) [8] . Mucinous adenocarcinomas which could not be classifi ed were excluded from analysis. If a study provided suffi cient data, analyses for both histological classifi cations (1 and 2) were made. Depth of tumor invasion in cancer limited to the mucosa was classifi ed as either presence or absence of invasion into the muscularis mucosae. Depth of tumor invasion in cancer limited to the submucosa was classifi ed as follows: (1) submucosal invasion of more or less than 500 μm, or (2) presence or absence of invasion beyond the upper third or middle third of the submucosa. If a study provided suffi cient data, analyses for both classifi cations of tumor invasion depth (1 and 2) were made. Vascular and lymphatic tumor invasion were both dichotomized into either presence or absence. If a study provided insufficient data, making a dichotomized classifi cation of either macroscopic tumor type, histological type, depth of tumor invasion, vascular tumor invasion, or lymphatic tumor invasion not possible, no analysis of that tumor parameter was made for the study concerned.
The numbers of patients with metastasis-positive and metastasis-negative LNs for each patient and/or tumor characteristic were abstracted from each study. A standard correction of adding 0.5 to all cells of the 2 × 2 contingency table was applied if there were no patients in one of the four cells. Study-specifi c odds ratios with 95% confi dence intervals (CIs) were calculated for positive versus negative LN status for each tumor/patient characteristic under investigation. The common odds ratios across studies were estimated by means of a Mantel-Haenszel fi xed-effects model, weighting individual studies by their variance [10] . Point estimates and 95% CIs for the common odds ratios were reported for characteristics supported by abstracted data from at least two studies. Confi dence intervals that did not overlap the referent (1.0) were considered to be statistically signifi cant. Heterogeneity was tested using the Higgins and Thompson test (Higgins et al. [11] ), calculating the I 2 statistic. This statistic uses the conventional Cochran's Q statistic to calculate the percentage of total variation across studies that can be attributed to interstudy heterogeneity, ranging from 0 (no heterogeneity) to 100% (all variance due to heterogeneity). In contrast to Cochran's Q, the I 2 is less affected by the number of studies included in a meta-analysis [11] . If no or moderate heterogeneity is found (I 2 ≤ 50%), pooling is justifi ed. Statistical analyses were executed using Meta-DiSc statistical software version 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain).
Results
The computer-aided search revealed 6246 articles from PubMed/MEDLINE. After screening titles and abstracts, 147 articles remained for possible inclusion. After reviewing the full article, 102 articles were excluded. Reasons for exclusion were: no separate analysis for mucosal and/or submucosal cancer was made or could be extracted (n = 71), insuffi cient data to construct a 2 × 2 contingency table to calculate the association of one or more patient and/or tumor characteristics with LN involvement (n = 13), no association between any patient and/or tumor characteristic and LN status in either mucosal or submucosal cancer was investigated (n = 10), same data used in another article by the same group, comprising a larger number of patients (n = 4), and only the association between patient and/or tumor characteristics and immunohistochemically detected LN micrometastases was determined (n = 4). Eventually, 45 studies were included in this systematic review [6, . Screening the references of these articles did not result in other potentially relevant articles. The characteristics of the included studies are presented in Table 1 . No studies meeting the inclusion criteria had a prospective study design. The number of patients per study for mucosal cancer varied between 18 and 3584 (median, 269). The number of patients per study for submucosal cancer varied between 22 and 2625 (median, 170). Twenty-six studies stated that patients were included in a consecutive way. Among these studies, the percentage of LN-positive cases in patients with mucosal cancer varied between 0.0 and 20.3% (median, 3.2%). For submucosal cancer, the percentage of LN-positive patients varied between 10.2% and 33.3% (median, 19.2%). In total, 18 different patient and/or tumor characteristics were investigated for mucosal cancer. For submucosal cancer, 24 different patient and/or tumor characteristics were investigated.
Mucosal cancer
In patients with mucosal cancer, there was no signifi cant association between sex, depth of mucosal tumor infi ltration, submucosal vascularity, infi ltration of dendritic cells, gastritis cystica profunda (GCP)-like glandular proliferation of the tumor, DNA ploidy, mucin phenotype, matrix metalloproteinase (MMP)-2 expression, and erbB-2 expression, and the presence of LN metastasis.
Variables signifi cantly associated with LN metastasis were: age younger than 57 years, tumor location in the middle part of the stomach, larger tumor size, macroscopically depressed tumor type, tumor ulcerations, undifferentiated tumors, diffuse tumor type according to the Lauren classifi cation [9] , lymphatic tumor The 102 most recent consecutive cases were also subjected to a careful pathologic examination to determine the extent of submucosal invasion c p53 expression was investigated in the 14 primary lesions with lymph node metastases and 14 randomly selected primary lesions without nodal involvement invasion, tumors with a proliferating cell nuclear antigen (PCNA) labeling index of more than 25%, and MMP-9 positive tumors (Fig. 1) . Among the studies investigating the variable "tumor ulcerations", more than moderate heterogeneity was identifi ed (I 2 = 55.8%).
Submucosal cancer
In patients with submucosal cancer, there was no signifi cant association between age (for various cutoff values), family history of gastric cancer, macroscopic tumor type, tumor ulceration, tumor type according to the Lauren classifi cation, tumor growth pattern, presence of fi brosis near the tumor, tumor stroma, infi ltration of dendritic cells, DNA ploidy, p53 overexpression, GCP-like glandular proliferation of the tumor, vascular endothelial growth factor (VEGF)-D expression, erbB-2 expression, and presence of LN metastasis.
Variables signifi cantly associated with LN metastasis were: female sex, tumor location in the lower part of the stomach, larger tumor size, undifferentiated tumors, increasing depth of submucosal invasion, lymphatic tumor invasion, vascular tumor invasion, increased submucosal vascularity, tumors with a PCNA labeling index of more than 25%, tumors with a gastric mucin phenotype, and VEGF-C-positive tumors (Fig. 2) . Among the studies investigating the variables "main histological tumor type (differentiated vs undifferentiated tumors)" and "vascular tumor invasion", more than moderate heterogeneity was identifi ed (with an I 2 of 82.5% and 51.3%, respectively). 
Discussion
The overall risk of LN metastasis in mucosal gastric cancer is only about 3.2% (see Results). In submucosal cancer, the risk of LN metastasis is approximately 19.2% (see Results). To date, no imaging modality has been proven to be consistently accurate in assessing LN metastasis in EGC. Endoscopic ultrasonography (EUS) mainly depends on LN echogenicity, morphology, and size as criteria to defi ne malignancy. Reported sensitivities and specifi cities of EUS to detect LN metastases in gastroesophageal carcinomas vary widely, between 59.5% and 97.2%, and between 40.0% and 100% [56] . Computed tomography (CT), another anatomical imaging modality, mainly uses LN size as a criterion to defi ne malignancy. Using a 64-section multidetectorrow CT scanner, a recent study found a sensitivity and specifi city of 84.2% (95% CI, 62.4-94.5) and 84.0% (95% CI, 65.4-93.6) [57] . Still, differentiating between benign and metastatic LNs may be unreliable when LN size is used as a criterion [58, 59] . 18 F-fl uoro-2-deoxyglucose positron emission tomography, a functional imaging modality based on the increased glycolytic rate of malignant cells [60] , has also been shown to be insuffi ciently accurate in assessing LN status in gastric cancer; although reported specifi cities vary between 90.0% and 97.0%, reported sensitivities vary between only 34.0% and 64.6% [61] [62] [63] . The accuracy of other functional imaging modalities, including magnetic resonance imaging (MRI) with ultrasmall particles of superparamagnetic iron oxide [64] and diffusion-weighted MRI [65] , still has to be investigated in large patient cohorts. Laparoscopic sentinel node (SN) biopsy is another promising tool to more accurately determine nodal status in EGC patients. The SN concept is based on the premise that tumor cells will preferentially metastasize to the fi rst draining LN in the regional lymphatics, the SN. After identifying the SN (by use of a radionucleotide tracer and/or dye), and laparoscopic biopsy, LN metastasis is confi rmed or ruled out by histological examination. A disadvantage of laparoscopic SN biopsy, however, is its invasiveness. Although studies on laparoscopic SN biopsy have shown its potential [66] [67] [68] [69] , various technical and material limitations still have to be overcome. Also, the reliability of laparoscopic SN biopsy has yet to be determined by multicenter prospective clinical trials [70] .
Because currently available imaging modalities fail to accurately determine nodal status, nodal status in EGC is still predicted by means of the presence or absence of certain tumor characteristics. According to the treatment guidelines of the Japanese Gastric Cancer Association (JGCA), EMR without lymphadenectomy is indicated in differentiated mucosal cancers less than 20 mm in size, and subtotal gastrectomy with D1 lymphadenectomy plus resection of the no. 7 (+8a) LNs is indicated in undifferentiated mucosal cancers, differentiated mucosal cancers 20 mm or more in size, and differentiated submucosal cancers 15 mm or less in size. For other submucosal cancers, the JGCA treatment guidelines indicate subtotal gastrectomy with D1 lymphadenectomy plus resection of the no. 7, 8a, and 9 LNs [5] . These criteria, however, may be too strict and can lead to unnecessary surgery [3, 6] . Gotoda et al. [6] proposed expanded criteria for the endoscopic treatment of EGC; using the variables "histological tumor type", "lymphatic-vascular involvement", "ulcer fi ndings", and "tumor size", they defi ned (additional) groups of patients with EGC who may also have been eligible for endoscopic tumor resection. However, for patients who did not belong to one of these groups, the risk of LN metastasis was not reported [6] . Furthermore, there may be more predictive variables allowing an even better risk assessment in the individual EGC patient.
The results of the present systematic review and meta-analysis show that variables signifi cantly associated with LN metastasis in mucosal cancer are: age younger than 57 years, tumor location in the middle part of the stomach, larger tumor size, macroscopically depressed tumor type, tumor ulcerations, undifferentiated tumors, diffuse tumor type according to the Lauren classifi cation [9] , lymphatic tumor invasion, tumors with a PCNA labeling index of more than 25%, and MMP-9-positive tumors (Fig. 1) . Patients with tumor ulcerations also had a signifi cantly higher risk of LN metastasis. However, more than moderate heterogeneity was identifi ed among the studies investigating this variable. An explanation for this heterogeneity may be the interobserver variability between studies for the assessment of tumor ulcerations. Also, none of the studies investigating this variable mentioned whether assessment of this variable was done blinded to LN status. Variables signifi cantly associated with LN metastasis in submucosal cancer are: female sex, tumor location in the lower part of the stomach, larger tumor size, undifferentiated tumors, increasing depth of submucosal invasion, lymphatic tumor invasion, vascular tumor invasion, increased submucosal vascularity, tumors with a PCNA labeling index of more than 25%, tumors with a gastric mucin phenotype, and VEGF-C-positive tumors (Fig. 2) . It should be noted that more than moderate heterogeneity was identifi ed among the studies investigating the variables "main histological tumor type (differentiated vs undifferentiated tumors)" and "vascular tumor invasion". This may be explained by interobserver variability between studies and the assessment of these variables unblinded to LN status. Another limitation is that certain variables, such as "PNCA labeling index", "MMP-9 expression", "mucin phenotype", and "VEGF-C expression", were investigated only by single and relatively small-sized studies. This is also expressed by their wide confi dence intervals (see Figs. 1 and 2) .
Lymphatic tumor invasion was the strongest univariate predictor for LN metastasis in both mucosal and submucosal gastric cancer. This is not surprising, as the lymphatics are the direct pathway to the LNs. However, the JGCA treatment guidelines are not based on the presence or absence of lymphatic tumor invasion [5] . JGCA treatment guidelines use a tumor size of 20 mm as the cutoff in differentiated mucosal cancer to decide for either endoscopic resection or modifi ed gastrectomy. This was based on the assumption that differentiated mucosal cancer of 20 mm or less has no LN metastasis, and also because 20 mm was the technical upper limit of en-bloc resection at the time the guidelines were composed [5] . However, newer endoscopic resection techniques allow the en-bloc resection of larger lesions [2] . Future studies should assess whether there is a signifi cant difference in LN metastasis risk between different tumor size cutoff values, after applying multivariate analysis to adjust for other variables. Notably, although a large size of carcinoma can contribute to contact between carcinoma cells and a lymphoid vessel, specifi c enzymes are necessary for the degradation of the vessel wall and for the invasion of the lymphoid vessel. MMPs are considered to be important for the facilitation of tumor invasion and spread [71] . Indeed, MMP-9 was signifi cantly associated with LN metastasis in mucosal cancer [31] . To our knowledge, the relation between MMPs and LN metastasis in submucosal cancer still has to be investigated. It should also be further explored which MMPs (or combinations of MMPs) are most predictive for LN metastasis.
Despite the fi ndings of our univariate analysis, confounding of variables may be present. For instance, lymphatic tumor invasion, vascular tumor invasion, and VEGF-C are all signifi cantly associated with LN metastasis, but tumor angiogenesis and lymphangiogenesis (which may both promote lymphatic and vascular tumor invasion) are also related to VEGF-C. In addition, it is also very likely that the variables "main tumor histology (differentiated vs undifferentiated type)" and "tumor histology according to the Lauren classifi cation" [9] are overlapping. Thus, future studies are needed to assess which variables are signifi cant predictors of LN metastasis after multivariate analysis. These variables can then be used to develop a model that can accurately predict the risk of LN metastasis in an individual patient.
Of note, in 1989 Kampschoer et al. [72] had already developed a computer program to predict the probability of LN metastasis, based on certain histopathological features of the primary tumor. However, the point at which LN dissection should be done, based on this program, is not clear [73] . In addition, the computer program is based only on the preoperative variables "sex", "age", "tumor location", "macroscopic type", "tumor size", "depth of tumor invasion", and "histological type" [72] . For instance, both lymphatic and vascular invasion, which proved to be strongly associated with LN metastasis by our analysis, were not used by the program.
It should also be noted that, in the study of Kampschoer et al. [72] , depth of tumor invasion and histological type were assessed by means of double-contrast X-rays and histological analysis of biopsied tissue. Endoscopic ultrasound was performed if results were inconclusive. Kampschoer et al. [72] stated that the preoperative diagnosis and classifi cation were correlated with the surgical fi ndings in 96.5% of cases, and that the extent of invasion could be accurately assessed because of the expertise of the radiologists. In actual practice, however, the accuracy of histopathologic grading using forceps biopsy specimens is only approximately 82.5% when compared to the fi nal histological typing based on the predominant histology of the resected tumor [74] . In addition, it is still unclear whether EUS, the current fi rst-choice imaging modality in T-staging, can accurately differentiate between mucosal and deeper gastric cancer [75] . When biopsy specimens do not refl ect the predominant histopathology of the entire tumor and/or the depth of invasion as assessed by EUS is greater than the actual depth, a decision may be made to perform surgery unnecessarily. Endoscopic resection, however, has the ability to provide complete histopathological staging (and assessing all variables) without precluding future surgery [3, 76] . Therefore, in all patients who are suspected of having EGC or in cases in which the biopsy-based histopathologic typing or EUSdetermined depth of invasion is thought to be unreliable, endoscopic resection should be performed as the fi rst step. Then, after evaluating the resected specimen, one can weigh the risks of LN metastasis against the risk of surgery.
Although the majority of the studies included in the present systematic review and meta-analysis were performed in Japan, it is likely that the results of this meta-analysis are generalizable, because the clinicopathological features of gastric cancer in Japan and Western countries do not seem to differ [77] . Of the included studies, 16% performed D2 or more extensive lymphadenectomy in all patients. D1 lymphadenectomy includes the removal of level 1 LNs only, whereas D2 lymphadenectomy adds the removal of level 2 LNs [8] . Although metastasis to level 2 LNs is rare, occurring in only 0.4% of patients with mucosal cancer and in 4.9% of patients with submucosal cancer [78] , some skip metastases may have been missed in patients who underwent less than D2 lymphadenectomy. Another limitation of the included studies is that all but one did not assess patient and/or tumor characteristics blinded to LN status, and vice versa, which may have introduced bias.
In conclusion, the present systematic review and meta-analysis identifi ed several variables that are associated with LN metastasis in EGC. These variables should be included in future research, in order to assess which of these variables remain as signifi cant predictors of LN metastasis.
